<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02817464</url>
  </required_header>
  <id_info>
    <org_study_id>TV46046-WH-10075</org_study_id>
    <nct_id>NCT02817464</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle</brief_title>
  <official_title>A Two-part, Phase 1, Exploratory and Dose-range Finding Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following a Single Subcutaneous Administration of TV-46046 in Women With Ovulatory Cycle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products, R&amp;D Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FHI 360</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pharmacodynamic and pharmacokinetic study is to identify a dose of
      TV-46046 (within the range 80 to 300 mg) that is both safe and consistent with contraceptive
      effect when injected every 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 7, 2016</start_date>
  <completion_date type="Anticipated">February 2, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum progesterone concentration</measure>
    <time_frame>Baseline, Days: 1, 2, 4, 6, 8, 10, 12; then weekly through week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Medroxyprogesterone acetate (MPA) concentration</measure>
    <time_frame>Baseline, Days: 1, 2, 3, 5, 7, 10, 12, 14, 18, 20; 28, 35, 42; then at weeks 8, 10, 12, 13, 15, 17, 19, 21, 23, 25, 26, 28, 30, and 32; and then every 28 days until week 52 (in Part 1)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed serum drug concentration at day 182 (Cmax)</measure>
    <time_frame>Baseline, Days: 1, 2, 3, 5, 7, 10, 12, 14, 18, 20; 28, 35, 42; weeks 8, 10, 12, 13, 15, 17, 19, 21, 23, 25, 26, 28, 30, and 32; and then every 28 days until week 52.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed serum drug concentration (tmax)</measure>
    <time_frame>Baseline, Days: 1, 2, 3, 5, 7, 10, 12, 14, 18, 20; 28, 35, 42; weeks 8, 10, 12, 13, 15, 17, 19, 21, 23, 25, 26, 28, 30, and 32; and then every 28 days until week 52.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum drug concentration by time curve from time 0 to day 182 (AUC0-182)</measure>
    <time_frame>Baseline, Days: 1, 2, 3, 5, 7, 10, 12, 14, 18, 20; 28, 35, 42; weeks 8, 10, 12, 13, 15, 17, 19, 21, 23, 25, 26, 28, 30, and 32; and then every 28 days until week 52.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration time-curves (AUC0-∞)</measure>
    <time_frame>Baseline, Days: 1, 2, 3, 5, 7, 10, 12, 14, 18, 20; 28, 35, 42; weeks 8, 10, 12, 13, 15, 17, 19, 21, 23, 25, 26, 28, 30, and 32; and then every 28 days until week 52.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal half-life</measure>
    <time_frame>Baseline, Days: 1, 2, 3, 5, 7, 10, 12, 14, 18, 20; 28, 35, 42; weeks 8, 10, 12, 13, 15, 17, 19, 21, 23, 25, 26, 28, 30, and 32; and then every 28 days until week 52.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observed serum drug concentration (Cmax)</measure>
    <time_frame>Day 7, week 13, 32, 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to observed serum drug concentration (tmax)</measure>
    <time_frame>Day 7, week 13, 32, 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed serum drug concentration at day 210 (C210)</measure>
    <time_frame>Day 7, week 13, 32, 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed serum drug concentration at day 182 (C182)</measure>
    <time_frame>Day 7, week 13, 32, 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum drug concentration by time curve from time 0 to day 182 (AUC0-182)</measure>
    <time_frame>Day 7, week 13, 32, 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma/serum drug concentration by time curve from time 0 to day 210 (AUC0-210)</measure>
    <time_frame>Day 7, week 13, 32, 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time-curves from time zero (AUC0-∞)</measure>
    <time_frame>Day 7, week 13, 32, 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>78 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Pregnancy</condition>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>TV-46046 - 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TV-46046 - 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TV-46046 - 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TV-46046 - 400 mg/mL</intervention_name>
    <description>A single subcutaneous injection in the abdomen of TV-46046 - 400 mg/mL</description>
    <arm_group_label>TV-46046 - 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TV-46046 - 200 mg/mL</intervention_name>
    <description>A single subcutaneous injection in the abdomen of TV-46046 - 200 mg/mL</description>
    <arm_group_label>TV-46046 - 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TV-46046 - 300 mg/mL (if warranted)</intervention_name>
    <description>A single subcutaneous injection in the abdomen of TV-46046 - 300 mg/mL (if warranted)</description>
    <arm_group_label>TV-46046 - 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  has regular menstrual cycle (24 to 35 days)

          -  is at low risk of pregnancy (ie, sterilized, in exclusively same-sex partnership, in
             monogamous relationship with vasectomized partner, or using non-hormonal IUD)

          -  is in good general health as determined by a medical history and physical examination

          -  is not pregnant and does not have desire to become pregnant in the subsequent 36
             months

          -  has had a normal mammogram within the last year (for Part 1 only)

               -  additional criteria apply, please contact the investigator for more information

        Exclusion Criteria:

          -  has hypertension:

               -  systolic blood pressure (BP) ≥160 mm Hg or diastolic BP ≥100 mm Hg

               -  vascular disease

          -  has current or history of ischemic heart disease

          -  has history of stroke

          -  has history of thromboembolic event

          -  has systemic lupus erythematosus

               -  positive (or unknown) antiphospholipid antibodies

               -  severe thrombocytopenia

          -  has rheumatoid arthritis on immunosuppressive therapy

          -  has migraine with aura

          -  has unexplained vaginal bleeding

          -  has diabetes

          -  has strong family history of breast cancer (defined as one or more first degree
             relatives, breast cancer occurring before menopause in three or more family members,
             regardless of degree of relationship, and any male family member with breast cancer),
             or current or history of breast cancer, or undiagnosed mass detected by breast exam

          -  has current or history of cervical cancer

          -  has severe cirrhosis (decompensated) or liver tumors

          -  has known significant renal disease

          -  used Depo-Provera Contraceptive Injection or Depo-subcutaneous Provera 104 (DMPA)
             products in the past 12 months

          -  used any of the following medications within 1 month prior to enrollment:

               -  any investigational drug

               -  prohibited drugs per protocol

               -  oral contraceptives, contraceptive ring or patch

               -  levonorgestrel intrauterine system (LNG IUS) or contraceptive implant

          -  used a combined injectable contraceptive in the past 6 months

          -  less than 3 months since the end of last pregnancy

          -  currently lactating

          -  is using or plans to use prohibited drugs per protocol in the next 18 months

          -  has known sensitivity to MPA or inactive ingredients

          -  has a plan to move to another location in the next 24 months

          -  in the opinion of the investigator, potentially at elevated risk of HIV infection (eg,
             HIV -positive partner, IV drug use by self or by partner)

               -  additional criteria apply, please contact the investigator for more information
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>TEVA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Site 001</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 002</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 003</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 004</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Dominican Republic</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

